

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-18 (canceled)

Claim 19 (previously presented): An ophthalmic, night vision formulation, comprising:

a sterile aqueous carrier; and

a therapeutically effective amount of a pharmaceutically active compound selected from the group consisting of an imidazoline, an alkylating agent, and an alpha 1 antagonist not including a piperazinyl quinazoline wherein the pharmaceutically active compound is capable of contracting a pupil of a human patient's eye so that the pupil in dim light is reduced by 1.0 mm or more.

Claim 20 (previously presented): The formulation of claim 19, wherein the pharmaceutically active compound is selected from the group consisting of a phenoxybenzamine and a phentolamine.

Claim 21 (previously presented): The formulation of claim 19, wherein the pharmaceutically active compound is present in a concentration in a range of from about 0.01 milligrams per cubic centimeter of solvent to about 50 milligrams per cubic centimeter of solvent.

Claim 22 (previously presented): The formulation of claim 19, wherein the sterile aqueous carrier comprises an ophthalmic artificial tear solution.

Claim 23 (new): An ophthalmic formulation, comprising:  
a therapeutically effective amount of an alpha 1 antagonist not including dapiprazole  
wherein the alpha 1 antagonist is capable of disrupting endogenous compounds which stimulate  
dilator muscles of a human eye.

Claim 24 (new): The formulation of claim 23, wherein the alpha 1 antagonist is selected  
from the group consisting of an imidazoline, an alkylating agent, phentolamine,  
phenoxybenzamine, prazosin, and tolamine.

Claim 25 (new): The formulation of claim 23, wherein the alpha 1 antagonist is  
present in a concentration in a range of from about 0.01 milligrams per cubic centimeter of  
solvent to about 50 milligrams per cubic centimeter of solvent.

Claim 26 (new): The formulation of claim 23, which includes a sterile aqueous  
carrier.

Claim 27 (new): The formulation of claim 26, wherein the sterile aqueous carrier  
comprises an ophthalmic artificial tear solution.